spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  LEXIVA 

 HSMN NewsFeed - 14 Mar 2013
Chimerix Appoints Michael D. Rogers, Ph.D., as Chief Development Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Aug 2010
Phase 3 ILLUMINATE Study Supports 24-Week Telaprevir-Based Therapy Within a Response-Guided Regimen for People with Hepatitis C Who Had Not Received Prior Treatment
Biopharmaceuticals
 HSMN NewsFeed - 19 Jul 2010
Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 28 Apr 2010
Abbott Receives FDA Approval for Once-Daily Dosing of Kaletra(R) (lopinavir / ritonavir) for Treatment-Experienced Patients
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 11 Feb 2010
Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 10 Dec 2009
Vertex Pharmaceuticals Announces Appointment of Nancy J. Wysenski as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Apr 2009
GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 18 Jun 2008
Vertex Pharmaceuticals Announces the Appointment of Freda C. Lewis-Hall, M.D., as Executive Vice President, Medicines Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Nov 2007
Vertex's Collaborator Merck Suspends Patient Enrollment in Clinical Trials of MK-0457 (VX-680) Pending Full Analysis of Clinical Data
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Nov 2007
First Studies Demonstrating Greater than Sixty Percent Sustained Viral Response Rates with Half the Standard Treatment Duration in Genotype 1 Chronic Hepatitis C Patients
Biopharmaceuticals
 HSMN NewsFeed - 25 Jul 2007
New Head-to-Head Study Comparing LEXIVA(R) and Atazanavir Show Similar Efficacy and Lipid Changes
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 29 Jun 2007
Vertex Pharmaceuticals Announces Two Executive Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Sep 2006
GlaxoSmithKline and Vertex Pharmaceuticals Announce Virologic and Drug Resistance Results from Protease Inhibitor Study
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 5 Sep 2006
Adnexus Therapeutics Expands and Strengthens Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Aug 2006
Head-to-Head Study Comparing LEXIVA(R) (fosamprenavir calcium) to Kaletra(R) Presented at IAC 2006 and Published in The Lancet
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 30 Jun 2006
Vertex Pharmaceuticals and Janssen Pharmaceutica, a Johnson & Johnson Company, Form Collaboration to Develop and Commercialize VX-950 for Treatment of Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2006
Vertex Pharmaceuticals Initiates the First of Two Major Phase II Studies of VX-950 in Treatment-Naive HCV Patients
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2006
Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients
Biopharmaceuticals
 HSMN NewsFeed - 16 May 2006
GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 7 Feb 2006
Vertex Successfully Completes Key Studies with VX-950 to Prepare for Next Steps in Clinical Program
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 32

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 32 additional stories matching:
LEXIVA
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.